August 6th Greetings, Friend!
Catch what was cooking Wednesday?
Our last Nasdaq profile surged from an open of $.6449 to a new 3+ month high of $.832.
That resulted in an intraday blast of approx. 29%.
Now, here's something new...
On June 30, 2026, the U.S. Food and Drug Administration granted Sonoma Pharmaceuticals (Nasdaq: SNOA) a new 510(k) clearance for its Microdacyn Wound Irrigation Solution, expanding approved uses to include pressure ulcers, diabetic foot ulcers, post-surgical wounds, and burns, while adding new consumer-facing packaging formats for over-the-counter sale.
It was the company's 23rd FDA 510(k) clearance in its history.
That number matters because it reflects not just one regulatory filing, but a sustained, multi-year commitment to verifying the safety and effectiveness of stabilized hypochlorous acid across an expanding range of clinical indications.
The clearance arrived just months after a pair of significant commercial events in March 2026.
First, Sonoma announced the nationwide retail launch of its Advanced Burn Relief Hydrogel in CVS and Walmart, placing an HOCl-based burn care product on pharmacy shelves across the United States.
A few days prior, the company unveiled Aquanil AD, a sensitive-skin dermatology product line built on its proprietary Microcyn technology and commercialized under the Aquanil brand, which belongs to Persōn & Covey, a California dermatology company with more than 80 years in the therapeutic skincare market.
Two separate product launches. Two distinct distribution channels. One calendar month.
The company's full-year fiscal 2026 results confirmed that this was not a coincidental burst of activity.
Total revenue reached $19.5Mn for the fiscal year ended March 31, 2026, a 37% increase over the prior year.
Fourth-quarter revenue of $5.6Mn reflected 48% year-over-year growth.
Most notably, U.S. revenue surged 117% for the full year, rising from roughly $2.6Mn to $5.6Mn, as domestic partnerships and retail placements converted into real commercial volume.
Much of that domestic momentum traces back to October 2025, when Sonoma and Medline Industries co-launched an HOCl wound cleanser into U.S. hospitals and home heal-thcare channels.
Medline, a privately held heal-thcare distributor with more than 39,000 employees operating across 100-plus countries, brought Sonoma direct access to an institutional distribution network the company could not have assembled independently at its current scale.
Meanwhile, Sonoma's flagship dermatology product, Reliefacyn Advanced, earned three independent clinical endorsements: the National Rosacea Society Seal of Acceptance, the National Eczema Association Seal of Acceptance, and the National Psoriasis Foundation Seal of Recognition.
Three separate patient advocacy organizations, each representing a distinct chronic skin condition, independently evaluated the product and found it suitable for sensitive and compromised skin, as announced by the company in its product recognition filing.
These developments are unfolding against a market backdrop that research firm Fortune Business Insights estimates at $1.90Bn in 2025 for the global hypochlorous acid market, expanding at a 6.4% compound annual growth rate toward $3.32Bn by 2034.
The heal-thcare and wound care segment is the fastest-growing application, driven by clinical evidence, physician awareness, and regulatory clarity built over many years of documented safety data. |
